文献速递临床试验与 GCP流行病学与生物统计

BEAT CF 肺部急性加重核心方案:评估囊性纤维化患者肺部急性加重管理

BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
PubMed 文献 · Trials · 2023-03-22

BEAT CF PEx 队列是一项前瞻性、多中心、持续性平台方案,纳入澳大利亚囊性纤维化治疗中心的成人和儿童患者,系统收集人口学、临床、治疗及结局数据。主要终点为强化治疗开始至7至10天后预测第1秒用力呼气容积百分比(ppFEV1)的绝对变化。该队列旨在作为未来嵌套干预试验的核心方案,评估肺部急性加重强化治疗干预措施的相对有效性。

要点

  • BEAT CF PEx 队列为前瞻性、多中心、持续性平台,纳入澳大利亚囊性纤维化治疗中心的成人和儿童患者。
  • 主要终点为强化治疗开始至7至10天后ppFEV1的绝对变化。
  • 该队列将作为核心方案,用于未来嵌套干预试验评估肺部急性加重治疗。

核心结论

  • BEAT CF PEx 队列将报告囊性纤维化患者肺部急性加重的临床、治疗和结局数据,旨在作为未来嵌套干预试验的核心方案。
  • 嵌套子研究的方案超出本文档范围,将另行报告。

研究设计与样本

  • 前瞻性、多中心、持续性平台,从澳大利亚囊性纤维化治疗中心开始,纳入所有年龄的临床诊断囊性纤维化患者,除外既往接受肺移植者。
  • 通过数字化集中试验管理系统(CTMS)系统收集并安全存储人口学和临床信息、治疗细节及结局(包括安全性、微生物学和患者报告结局指标含生活质量评分)。
  • 主要终点为强化治疗开始至7至10天后预测第1秒用力呼气容积百分比(ppFEV1)的绝对变化。

关键数值与推荐

  • 主要终点为强化治疗开始至7至10天后ppFEV1的绝对变化。
  • 纳入标准:所有年龄临床诊断囊性纤维化者;排除标准:既往接受肺移植者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases. Here, we present the protocol for the BEAT CF PEx cohort, a prospective, multi-site, perpetual, platform enrolling adults and children with CF. The BEAT CF PEx cohort will be used to evaluate the comparative effectiveness of interventions for the treatment of PEx requiring intensive therapy (PERITs), with a primary focus on short-term improvements in lung function. This will be achieved through the conduct of cohort-nested studies, including adaptive clinical trials, within the BEAT CF PEx cohort. This protocol will outline key features of the BEAT CF PEx cohort, including the design, implementation, data collection and management, governance and analysis, and dissemination of results. METHODS: This platform will be conducted across multiple sites, commencing with CF treatment centers in Australia. People of all ages with a clinical diagnosis of CF will be eligible to participate, except those who have previously received a lung transplant. Data including demographic and clinical information, treatment details, and outcomes (including safety, microbiology, and patient-reported outcome measures including quality of life scores) will be systematically collected and securely stored via a digital centralized trial management system (CTMS). The primary endpoint is the absolute change in the percentage predicted forced expiratory volume in 1 s (ppFEV1) from the commencement of intensive therapy to 7 to 10 days afterwards. DISCUSSION: The BEAT CF PEx cohort will report clinical, treatment, and outcome data for PEx among people with CF and is intended to serve as a core (master) protocol for future nested, interventional trials evaluating treatment(s) for these episodes. The protocols for nested sub-studies are beyond the scope of this document and will be reported separately. TRIAL REGISTRATION: ANZCTR BEAT CF Platform - ACTRN12621000638831. Registration date: Sept. 26, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Schultz A, McLeod C, Berry S, et al. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis. Trials. 2023. PMID: 36949472. doi:10.1186/s13063-023-07076-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。